Shefali Agarwal
Chief Executive Officer chez VALERIO THERAPEUTICS
Fortune : 76 997 $ au 31/03/2024
Profil
Shefali Agarwal is currently the Chairman, President & Chief Executive Officer at Valerio Therapeutics SA, an Independent Director at Fate Therapeutics, Inc., and an Independent Director at Gritstone bio, Inc. She previously served as the Chief Medical Officer at SQZ Biotechnologies Co. from 2017 to 2018 and as the Executive VP, Chief Medical & Development Officer at Epizyme, Inc. from 2018 to 2022.
Dr. Agarwal holds a graduate degree from The Johns Hopkins University, a doctorate degree from Karnataka University, and a graduate degree from Merrick School of Business.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
FATE THERAPEUTICS, INC.
0,01% | 06/06/2023 | 10 490 ( 0,01% ) | 76 997 $ | 31/03/2024 |
GRITSTONE BIO, INC.
-.--% | 16/06/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de Shefali Agarwal
| Sociétés | Poste | Début |
|---|---|---|
| FATE THERAPEUTICS, INC. | Director/Board Member | 15/07/2019 |
| GRITSTONE BIO, INC. | Director/Board Member | 01/06/2021 |
| VALERIO THERAPEUTICS | Chief Executive Officer | 06/04/2022 |
Anciens postes connus de Shefali Agarwal
| Sociétés | Poste | Fin |
|---|---|---|
| EPIZYME, INC. | Chief Tech/Sci/R&D Officer | 06/04/2022 |
| SQZ BIOTECHNOLOGIES COMPANY | Chief Tech/Sci/R&D Officer | 01/05/2018 |
Formation de Shefali Agarwal
| The Johns Hopkins University | Graduate Degree |
| Karnataka University | Doctorate Degree |
| Merrick School of Business | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| SQZ BIOTECHNOLOGIES COMPANY | Health Technology |
| VALERIO THERAPEUTICS | Health Technology |
| FATE THERAPEUTICS, INC. | Health Technology |
| GRITSTONE BIO, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Epizyme, Inc.
 Epizyme, Inc. BiotechnologyHealth Technology Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA. | Health Technology |
